Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4249-4254

  Caffrey, Paula B ^a   Frenkel, Gerald D ^b  

^a CALIFORNIA UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Carboplatin; Drug resistance; Ovarian cancer; Selenite; Xenografts

Indexed keywords

CARBOPLATIN; CISPLATIN; SELENITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MEGADOSE; FEMALE; INDUCED RESISTANCE; INOCULATION; LOW DRUG DOSE; MOUSE; NONHUMAN; OVARY TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

CARBOPLATIN; DRUG RESISTANCE; OVARIAN CANCER; SELENITE; XENOGRAFTS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; SELENIOUS ACID; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891368150     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chabner BA and Roberts TG: Chemotherapy and the war on cancer. Nat Rev Cancer 5: 65-72, 2005.
2. Moscow J, Morrow CS and Cowan K: Drug resistance and its clinical circumvention. In: Holland-Frei Cancer Medicine Sixth Edition. Kufe, DW, Pollock RE, Weichselbaum RR, Bast RC Jr., Gansler TS, Holland JF and Frei E III (eds.). Hamilton, Decker, Chapter 48, 2003.
3. Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
4. Gottesman M: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
5. Frenkel GD and Caffrey PB: A prevention strategy for circumventing drug resistance in cancer chemotherapy. Curr Pharmaceut Design 7: 1595-1614, 2001.
6. Caffrey PB and Frenkel GD: Selenium compounds prevent the induction of resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol 46: 74-78, 2000.
7. du Bois A, Lück HJ, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329, 2003.
8. Jung HJ and Seo YR: Current issues of selenium in cancer chemoprevention. Biofactors 36: 153-158, 2010.
9. Hu H, Li GX, Wang L, Watts J, Combs GF Jr. and Lü J: Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and downregulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 14: 1150-1158, 2008.
10. Hu H, Jiang C, Ip C, Rustum YM and Lu J: Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 11: 2379-2388, 2005.
11. Li S, Zhou Y, Dong Y and Ip C: Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res 27: 3075-3082, 2007.
12. Li S, Zhou Y, Wang R, Zhang H, Dong Y and Ip C: Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Therapeutics 6: 1031-1038, 2007.
13. Qi Y, Fu X, Xiong Z, Zhang H, Hill SM, Rowan BG and Dong Y: Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS ONE 7: e31539, 2012.
14. Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME and Rowan BG: Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 118: 33-43, 2009.
15. Cao S, Durrani FA and Rustum YM: Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10: 2561-2569, 2004.
16. Chintala S, Tomicronth K, Cao S, Durrani FA, Vaughan MM, Jensen RL and Rustum YM: Se-Methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α. Cancer Chemother Pharmacol 66: 899-911, 2010.
17. Tan Q, Li J, Yin HW, Wang LH, Tang WC, Zhao F, Liu X and Zeng H: Augmented antitumor effects of combination therapy of cisplatin with ethaselen. Invest New Drugs 28: 205-215, 2010.
18. Hu Y, Chen Y, Zhang Y-Q, Zhou M-Z, Song X-M, Zhang B-Z, Luo L, Xu P-M, Zhao Y-N, Zhao Y-B and Cheng G: The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Element Res 56: 331-341, 1997.
19. Federico A, Lodice P, Federico P, Del Rio A, Mellone M, Catalano G and Federico P: Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur J Clin Nutr 55: 293-297, 2001.
20. Sieja K and Talerczyk M: Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 93: 320-327, 2004.
21. Zhang J, Peng D, Lu H and Liu Q: Attenuating the toxicity of cisplatin by using selenosulfate with reduced risk of selenium toxicity as compared with selenite. Toxicol Appl Pharmacol 226: 251-259, 2008.
22. Caffrey PB and Frenkel GD: Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance. Anticancer Res 18: 3017-3020, 1998.
23. Caffrey PB and Frenkel GD: Selenite enhances and prolongs the efficacy of cisplatin treatment of human ovarian tumor xenografts. In Vivo 26: 549-552, 2012.
24. Gounder MK, Gibbon D, Kumar C, Simmons N, Buckley B, Xie R, Lin Y, Shih W, Frenkel GD, Caffrey PB, Rubin E and Rodriguez-Rodriguez L: A Phase I pharmacokinetic study of paclitaxel and carboplatin combined with sodium selenite in patients with gynecologic malignancies. Proc 96th Meet Am Assoc Cancer Res Anaheim, CA., Abstract # 3983, 2005.
25. Godwin A, Meister A, O'Dwyer P, Huang C, Hamilton T and Anderson M: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
26. Yao K, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ and Hamilton TC: Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367-4374, 1995.
27. Glaysher S, Gabriel FG, Johnson P, Polak M, Knight LA, Parker K, Poole M, Narayanan A and Cree IA: Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer 103: 656-662, 2010.